Clinical trial · Interventional
Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
COX-2 Activity in Early and Advanced NSCLC and The Effect of Short-Term Administration of Specific COX-2 Inhibitors (Celecoxib)
NCT00653250CI-TRIAL-00010373completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This clinical trial is studying celecoxib in treating patients with stage I, stage II, or stage IIIA non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biopsy | Procedure | — | UNRESOLVED |
| celecoxib | Drug | Celecoxib | ALIAS |
| therapeutic conventional surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Therapeutic Intervention
- description
- Correlative
- interventionNames
- Drug: celecoxib
- Procedure: biopsy
- Procedure: therapeutic conventional surgery
Primary outcomes (1)
- measure
- Correlation of expression of cyclo-oxygenase-2 (COX-2) activity with serum VEGF levels, tumor microvessel density score, tumor PEG2 and MMP levels, and urinary PGE-M
- timeFrame
- Date of pretreatment biopsy surgery (tissue) and day 1 (blood)
- description
- COX-2 will be measured in pre-treatment tumor biopsy tissue as well as tumor microvessel density, MMP-2 and PGE2. VEGF will be measured in pre-treatment blood.
Secondary outcomes (1)
- measure
- Effect of Celecoxib on COX-2 expression and microvascular density in tumor, PGE2 and MMP levels in tumor, serum VEGF levels and urinary PGE-M
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Presumed histological or cytological diagnosis of non-small cell lung cancer * Diagnosis to be confirmed upon study entry to collect biopsy material for correlative studies * Stage I-IIIA disease PATIENT CHARACTERISTICS: * ECOG performance status of 0-2 * Serum creatinine ≤ 1.5 mg/dL * Granulocytes ≥ 1,500/mm\^3 * Platelets ≥ 100,000/mm\^3 * AST ≤ 3 times normal * Bilirubin ≤ 1.5 mg/dL * Not pregnant or nursing * Fertile patients must use effective contraception * No active unresolved infection PRIOR CONCURRENT THERAPY: * At least 7 days since prior and no concurrent non-steroidal anti-inflammatory agents or other cyclo-oxygenase-2 inhibitors * At least 7 days since prior parenteral antibiotics * No prior systemic chemotherapy or radiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.